Research Original Investigation Assessing Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions beliefs and practices. Clin Pharmacol Ther. 2018;103 31. Kesselheim AS, Bykov K, Gagne JJ, Wang SV, Published October 2019. Accessed May 19, 2020. (6):1093-1099. doi:10.1002/cpt.884 Choudhry NK. Switching generic antiepileptic drug https://ec.europa.eu/docsroom/documents/38461/ manufacturer not linked to seizures: attachments/1/translations/en/renditions/native 26. González López-Valcárcel B, Librero J, a case-crossover study. Neurology. 2016;87(17): García-Sempere A, et al. Effect of cost sharing on 37. US Department of Health and Human Services. 1796-1801. doi:10.1212/WNL.0000000000003259 adherence to evidence-based medications in American patients first: the Trump Administration patients with acute coronary syndrome. Heart. 32. Sarpatwari A, Avorn J, Kesselheim AS. Progress blueprint to lower drug prices and reduce 2017;103(14):1082-1088. doi:10.1136/heartjnl-2016- and hurdles for follow-on biologics. N Engl J Med. out-of-pocket costs. Published May 2018. Accessed 310610 2015;372(25):2380-2382. doi:10.1056/ June 7, 2020. https://www.hhs.gov/sites/default/ NEJMp1504672 files/AmericanPatientsFirst.pdf 27. Heidari P, Cross W, Crawford K. Do out-of-pocket costs affect medication adherence in 33. Whyte LE, Wieder B. Amid federal gridlock, 38. Avorn J, Soumerai SB. Improving drug-therapy adults with rheumatoid arthritis? a systematic lobbying rises in the states. The Center for Public decisions through educational outreach: review. Semin Arthritis Rheum. 2018;48(1):12-21. Integrity. Updated May 18, 2016.
JAMA Internal Medicine – American Medical Association
Published: Jan 31, 2021